Prevention of Marrow Graft Rejection by Cultured CD8 Blasts
| T Cells Added . | Number of T Cells . | IL-2 . | Recipients Tested . | Recipients Engrafted . | Percent Engrafted . |
|---|---|---|---|---|---|
| None | — | No | 10 | 0 | 0 |
| None | — | Yes | 10 | 0 | 0 |
| CD8 blasts | 5.0 × 104 | No | 5 | 0 | 0 |
| CD8 blasts | 5.0 × 104 | Yes | 10 | 0 | 0 |
| CD8 blasts | 2.5 × 105 | No | 9 | 3 | 33 |
| CD8 blasts | 2.5 × 105 | Yes | 15 | 6 | 40 |
| CD8 blasts | 1.0 to 1.2 × 106 | No | 9 | 9 | 100 |
| CD8 blasts | 1.0 to 1.2 × 106 | Yes | 10 | 10 | 100 |
| LN T | 1.0 to 1.2 × 106 | No | 9 | 9 | 100 |
| T Cells Added . | Number of T Cells . | IL-2 . | Recipients Tested . | Recipients Engrafted . | Percent Engrafted . |
|---|---|---|---|---|---|
| None | — | No | 10 | 0 | 0 |
| None | — | Yes | 10 | 0 | 0 |
| CD8 blasts | 5.0 × 104 | No | 5 | 0 | 0 |
| CD8 blasts | 5.0 × 104 | Yes | 10 | 0 | 0 |
| CD8 blasts | 2.5 × 105 | No | 9 | 3 | 33 |
| CD8 blasts | 2.5 × 105 | Yes | 15 | 6 | 40 |
| CD8 blasts | 1.0 to 1.2 × 106 | No | 9 | 9 | 100 |
| CD8 blasts | 1.0 to 1.2 × 106 | Yes | 10 | 10 | 100 |
| LN T | 1.0 to 1.2 × 106 | No | 9 | 9 | 100 |
Groups of five irradiated (800 cGy) CB6 recipients were transplanted with T-cell–depleted marrow (5.0 × 106cells) from B6C3 donors. Grafts contained no added T cells (negative control), 1.0 to 1.25 × 106 freshly isolated B6C3 lymph node T cells (LN T) (positive control), or the indicated numbers of CD8 blasts recovered on day 5 from MLC in which B6C3 LN T cells were stimulated with irradiated CB6 spleen cells. IL-2 (2,000 U IP) was administered daily for 6 days starting on the day of the transplant. Engrafted recipients had 86% to 99% (mean, 95.4%) H2k-positive donor-derived granulocytes in the blood at 2 months after transplantation, whereas recipients with rejection had 0% to 9% (mean, 1.9%) H2k-positive granulocytes when last tested at 1 to 2 months after transplantation. The table shows results pooled from three experiments.